Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

EZH2 inhibitors could help reverse immune evasion in DLBCL

Publish date:: April 8, 2020

Key clinical point: EZH2 inhibitors restore suppressed CD58 expression of lymphoma cells.

Major finding: EZH2 inhibitors enhance production of T and NK cells against lymphoma cells.

Study details: Epigenetic compound library screening using a B-cell lymphoma line with decreased CD58 expression.

Disclosures: The study was funded by the Japan Society for the Promotion of Science. Two authors received funding from Eisai Co., Ltd. The other authors declare no potential conflicts.

Citation:

Otsuka Y et al. Molecular Immunology. 2020;119:35-45.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,